Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
Overview
Chemistry
Molecular Biology
Affiliations
Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and complex genomic state, characterized by high intratumor heterogeneity (ITH) due to chromosomal instability that distinguishes HGSOCs. Histologically, these cancers exhibit significant morphological diversity both within and between tumors. The histologic patterns associated with solid, endometrioid, and transitional (SET) and classic subtypes of HGSOCs offer prognostic insights and may indicate specific molecular profiles. The evolution of HGSOC from primary to metastasis is typically characterized by clonal ITH, involving shared or divergent mutations in neoplastic sub-clones within primary and metastatic sites. Disease progression and therapy resistance are also influenced by non-clonal ITH, related to interactions with the tumor microenvironment and further genomic changes. Notably, significant alterations occur in nonmalignant cells, including cancer-associated fibroblast and immune cells, during tumor progression. This review provides an overview of the complex nature of HGSOC, encompassing its various aspects of intratumor heterogeneity, histological patterns, and its dynamic evolution during progression and therapy resistance.
Jackson G, Adamson D Cells. 2025; 14(3).
PMID: 39936963 PMC: 11816616. DOI: 10.3390/cells14030171.
Leveraging Multi-omics to Disentangle the Complexity of Ovarian Cancer.
Lin S, Nguyen L, McMellen A, Leibowitz M, Davidson N, Spinosa D Mol Diagn Ther. 2024; 29(2):145-151.
PMID: 39557776 DOI: 10.1007/s40291-024-00757-3.
Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems.
Lin Q, Li J, Abudousalamu Z, Sun Y, Xue M, Yao L Int J Nanomedicine. 2024; 19:9351-9370.
PMID: 39282574 PMC: 11401532. DOI: 10.2147/IJN.S478313.
SMARCA4‑deficient uterine adnexal tumor with ascites: A case report and literature review.
Li X, Zhang Y, Wei L, Wang Z, Yang M Oncol Lett. 2024; 28(2):357.
PMID: 38881708 PMC: 11176891. DOI: 10.3892/ol.2024.14490.
Meng Q, Zheng W, Jiao R, Cui R, Deng Y, Liu R Am J Cancer Res. 2024; 14(5):2643-2660.
PMID: 38859864 PMC: 11162662. DOI: 10.62347/UHEY7375.